Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607090 | 1.00 | CA1 (0.35) | CA1CA2CA14SMN1; SMN2CA12 | |
| SCHEMBL14405592 | 1.00 | CA1 (0.35) | CA1CA2CA14SMN1; SMN2CA12 | |
| SCHEMBL23709869 | 0.85 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12485083 | 0.81 | CTSS (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL733523 | 0.80 | SMN1; SMN2 (0.41) | CA14SMN1; SMN2CA12CA7CA9 | |
| SCHEMBL1439238 | 0.80 | SMN1; SMN2 (0.41) | CA14SMN1; SMN2CA12CA7CA9 | |
| SCHEMBL30771497 | 0.80 | SMN1; SMN2 (0.41) | CA14SMN1; SMN2CA12CA7CA9 | |
| SCHEMBL10201896 | 0.79 | SMN1; SMN2 (0.35) | CA14SMN1; SMN2CA12 | |
| SCHEMBL1439235 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL1188859 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| EP-1265603-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1265603-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6767922-B2 | ADMINISTERING N-(3-AMINOSULFONYL-2-HYDROXYPHENYL)-UREA DERIVATIVES; TREATMENT OF RESPIRATORY AND NERVOUS SYSTEM DISORDERS; ARTHRITIS, ASTHMA; VIRICIDES | SMITHKLINE BEECHAM CORPORATION | 2004-07-27 | — | — | US | disclosed |
| US-20030065188-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| EP-1265603-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068570-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-0207358-A2 | Growth-promoting agent | BAYER AG (DE) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065188-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CA1 3382/4885CA2 3402/4885CA14 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.